Daiichinkyo CoDSNKY +1.89%73 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates DSNKY with a GF Score™ of 73/100 and a GF Value™ of $37.98 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 684 Drug Manufacturers companies, Daiichinkyo Co ranks better than 64.33% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Daiichinkyo Co's
Operating Income
for the
three
months ended in Mar. 2026 was $-30 Mil. Daiichinkyo Co's Interest Expense for the
three
months ended in Mar. 2026 was $-22 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Daiichinkyo Co's Interest Coverage or its related term are showing as below:
DSNKY'
s Interest Coverage Range Over the Past 10 Years
Min: 11.53 Med: 17.92 Max: 35.11
Current: 28.69
DSNKY's Interest Coverage is ranked better than 64.33% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs DSNKY: 28.69
Daiichinkyo Co (OTCPK:DSNKY) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Daiichinkyo Co Interest Coverage Related Terms
Daiichinkyo Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
DSNKY vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Daiichinkyo Co did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Daiichinkyo Co (DSNKY) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Daiichinkyo Co and its competitors. Over the past decade, Daiichinkyo Co's Interest Coverage has ranged from 11.53 to 35.11. According to the industry distribution chart, Daiichinkyo Co ranks #244 out of 684 companies in the Drug Manufacturers industry, placing it in the top 35.7%.
Is Daiichinkyo Co's Interest Coverage too high?
Daiichinkyo Co's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 11.53 to a high of 35.11. Based on the distribution chart, Daiichinkyo Co ranks #244 out of 684 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Daiichinkyo Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #244 out of 684 companies for Interest Coverage. This puts Daiichinkyo Co in the upper half of its industry. The industry median Interest Coverage is 12.77. Historically, Daiichinkyo Co's own Interest Coverage has ranged from 11.53 to 35.11 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (DSNKY) is currently considered Significantly Undervalued. The stock's GF Value™ is $37.98, compared to a current price of $16.15 — trading 57.5% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Daiichinkyo Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Daiichinkyo Co (DSNKY), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (DSNKY) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of $16.15 is trading 57.5% below its estimated GF Value™ of $37.98.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for DSNKY:
Interest Coverage: 0 (At Loss)
GF Value™: $37.98 vs. price of $16.15 (57.5% below fair value)
No single metric tells the full story. See the DSNKY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
73GF Score
Get the complete analysis for DSNKY
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSNKY has been successfully added to your 
